Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2016: 1.000
Source Normalized Impact per Paper (SNIP) 2016: 1.112

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 44, Issue 3 (Mar 2006)

Issues

Time-resolved fluorimetric immunoassay of calprotectin: technical and clinical aspects in diagnosis of inflammatory bowel diseases

Gertjan van der Sluijs Veer
  • Department of Clinical Chemistry, Medisch Spectrum Twente Hospital, Enschede, The Netherlands
/ Barbara van den Hoven
  • Department of Clinical Chemistry, Medisch Spectrum Twente Hospital, Enschede, The Netherlands
/ Maurice G.V.M. Russel
  • Department of Internal Medicine, Medisch Spectrum Twente Hospital, Enschede, The Netherlands
/ Frank A.J.T.M. van den Bergh
  • Department of Clinical Chemistry, Medisch Spectrum Twente Hospital, Enschede, The Netherlands
Published Online: 2011-09-21 | DOI: https://doi.org/10.1515/CCLM.2006.051

Abstract

Background: Growing evidence in the literature shows the clinical importance of the calprotectin assay in faeces, especially for the differential diagnosis and monitoring of patients with inflammatory bowel diseases.

Methods: We developed a time-resolved fluorimetric immunoassay for calprotectin to extend the limited measuring range of the commercially available ELISA method currently used in our laboratory. Together with the introduction of a non-enzymatic label, this new method offers the advantages of better precision and higher sensitivity.

Results: The new assay shows a dynamic measuring range extended by a factor four, which reduces the number of samples with concentrations outside the measuring range from 30% to only 4%. The value of the assay was confirmed in various patient groups suffering from active and inactive gastrointestinal diseases. We suggest that the frequent coincidence of a high calprotectin concentration with intestinal blood loss is not the consequence of mere blood loss, but can be ascribed to neutrophil infiltration and subsequent shedding into the intestinal lumen as a result of intestinal inflammation or malignancy.

Conclusion: We expect that in the near future faecal calprotectin will be used as a non-invasive routine diagnostic marker and an effective laboratory parameter to monitor patients with inflammatory bowel disease.

Keywords: calprotectin; Crohn's disease; inflammatory bowel disease; irritable bowel syndrome; time-resolved fluorimetric immunoassay; ulcerative colitis

References

  • 1.

    Steinbakk M, Naess-Andresen CF, Lingaas E, Dale I, Brandtzaeg P, Fagerhol MK. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 1990; 336:763–5.Google Scholar

  • 2.

    Van den Bos C, Roth J, Koch HG, Hartmann M, Sorg C. Phosphorylation of MRP14, and S100 protein expressed during monocytic differentiation, modulates Ca(2+)-dependent translocation from cytoplasm to membranes and cytoskeleton. J Immunol 1996; 156:1247–54.Google Scholar

  • 3.

    Frosch M, Strey A, Vogl T, Wulffraat NM, Kuis W, Sunderkotter C, et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000; 43:628–37.Google Scholar

  • 4.

    Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in faeces. A methodologic study. Scand J Gastroenterol 1992; 27:793–8.Google Scholar

  • 5.

    Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999; 34:50–4.Google Scholar

  • 6.

    Fagerhol MK. Calprotectin, a faecal marker of organic gastrointestinal abnormality. Lancet 2000; 356:1783–4.Google Scholar

  • 7.

    Tibble JA, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000; 47:506–13.Google Scholar

  • 8.

    Summerton CB, Longlands MG, Wiener K, Shreeve DR. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 2002; 14:823–45.CrossrefGoogle Scholar

  • 9.

    Gaya DR, Lyon TD, Duncan A, Neilly JB, Han S, Howell J, et al. Faecal calprotectin in the assessment of Crohn's disease activity. QJM 2005; 98:435–41.Google Scholar

  • 10.

    Wassell J, Dolwani S, Metzner M, Losty JH, Hawthorne A. Faecal calprotectin: a new marker for Crohn's disease? Ann Clin Biochem 2004; 41:230–2.Google Scholar

  • 11.

    Tøn H, Brandsnes Ø, Dale S, Holtlund J, Skuibina E, Schjønsby H, et al. Improved assay for faecal calprotectin. Clin Chim Acta 2000; 292:41–54.Google Scholar

  • 12.

    Van der Sluijs Veer G, Soons JW. A time-resolved fluoroimmunoassay of the IgM-rheumatoid factor. Eur J Clin Chem Clin Biochem 1992; 30:301–5.Google Scholar

  • 13.

    Hemmilä I. Lanthanides as probes for time-resolved fluorometric immunoassays. Scand J Clin Lab Invest 1998; 48:389–400.CrossrefGoogle Scholar

  • 14.

    Hemmilä I. Applications of fluorescence in immuno-assays. New York: Wiley-Interscience, 1991.Google Scholar

  • 15.

    Hemmilä I, Dakabu S, Mukkala V-M, Siitari H, Lövgren T. Europium as a label in time-resolved immunofluorometric assays. Anal Biochem 1984; 137:335–43.Google Scholar

  • 16.

    Hessian PA, Fisher L. The heterodimeric complex of MRP-8 (S100A8) and MRP-14 (S100A9). Antibody recognition, epitope definition and implications for structure. Eur J Biochem 2001; 268:353–63.Google Scholar

  • 17.

    Goebeler M, Roth J, Teigelkamp S, Sorg C. The monoclonal antibody MAC387 detects an epitope on the calcium-binding protein MRP14. J Leukoc Biol 1994; 55:259–61.Google Scholar

  • 18.

    Holtund J, Dale S, Fagerhol MK. Process for the extraction of proteins. PCT International Publication Number WO 98/20355, 14 May 1998.Google Scholar

  • 19.

    Hanauer SB, Meyers S. Management of Crohn's disease in adults. Am J Gastroenterol 1997; 92:559–66.Web of ScienceGoogle Scholar

  • 20.

    Kristinsson J, Armbruster CH, Ugstad M, Kriwanek S, Nygaard K, Ton H, et al. Faecal excretion of calprotectin in colorectal cancer: relationship to tumor characteristics. Scand J Gastroenterol 2001; 36:202–7.Google Scholar

  • 21.

    Kronborg O, Ugstad M, Fuglerud P, Johne B, Hardcastle J, Scholefield JH, et al. Faecal calprotectin levels in a high risk population for colorectal neoplasia. Gut 2000; 46:795–800.Google Scholar

  • 22.

    Van den Bergh FA, Kolkman JJ, Russel MG, Vlaskamp RT, Vermes I. Calprotectine: een fecale marker voor diagnostiek en follow-up bij patiënten met chronische inflammatoire darmafwijkingen. Ned Tijdschr Geneesk 2003; 147:2360–5.Google Scholar

  • 23.

    Tibble JA, Sigthorsson G, Foster R, Sherwood R, Fagerhol M, Bjarnason I. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 2001; 49:402–8.Google Scholar

  • 24.

    Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119:15–22.Google Scholar

  • 25.

    Costa F, Mumola MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005; 54:364–8.Google Scholar

About the article

Corresponding author: G. van der Sluijs Veer, Medisch Spectrum Twente, Laboratorium, Postbus 50000, 7500 KA, Enschede, The Netherlands Phone: +31-53-4873400, Fax: +31-53-4873075,


Received: 2005-10-06

Accepted: 2005-12-05

Published Online: 2011-09-21

Published in Print: 2006-03-01


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2006.051.

Export Citation

©2006 by Walter de Gruyter Berlin New York. Copyright Clearance Center

Comments (0)

Please log in or register to comment.
Log in